Skip to content
Join our Newsletter

Canadians warm up to harm reduction in fight against opioids

Next month will mark the 16th anniversary of the start of operations at Insite, the first legal supervised drug injection facility to operate in North America.

Next month will mark the 16th anniversary of the start of operations at Insite, the first legal supervised drug injection facility to operate in North America. Since 2003, 48 similar sites have opened across Canada, more than half of which are located in Ontario.

The ongoing opioid crisis has hit British Columbia especially hard. The numbers are staggering. From January 2016 to September 2018, the deaths of more than 10,300 Canadians have been linked to opioid--related causes. More than 3,500 of these fatalities occurred in British Columbia.

Earlier this year, the federal government committed more than $15 billion to projects that aim to reverse this horrific trend. Four “harm reduction” strategies will benefit from $1.3 billion in federal funds, including the provision of supervised inhalation services in Surrey and a peer service coordinator on Vancouver Island.

Our views on drugs have gone through drastic changes over the past two decades. In October 2018, 64% of British Columbians told Research Co. that the use of prescription and non-prescription opioid drugs in their community is a “major problem.” Across Canada, drug use is no longer confined to “some” urban areas.

As more supervised injection facilities are authorized, there is no doubt about the growth of this crisis. With this in mind, Research Co. asked Canadians to review five measures that could be implemented to deal with drug use in the country. The results outline a population that is looking at the issue holistically.

The most popular idea, with the backing of 83% of Canadians, is to support “education and prevention campaigns.” The federal government has advertised extensively in various platforms, focusing efforts primarily on awareness and ending stigma.

Almost three in five Canadians are in favour of “supervised injection sites” (59%) and “needle-exchange programs” (58%). These projects are no longer regarded as “radical” by many politicians, like they were at the beginning of this century.

As expected, the views on supervised injection sites fluctuate on a regional basis. While-two thirds of Quebecers (68%) approve of this measure, acceptance drops to 63% in Manitoba and Saskatchewan, 59% in Atlantic Canada, 52% in both Ontario and British Columbia and 49% in Alberta.

The physical location of supervised injection sites plays a role in the way respondents react. While most Canadians (52%) would approve of having one of these facilities “anywhere in their municipality,” the proportion drops to 38% for one located “anywhere in their neighbourhood” and 32% for one placed “a block away from their home.”

In Alberta, where eight supervised injection sites have been approved and two more are “awaiting key information before a decision can be taken,” public views are more negative than anywhere else in the country.

Fewer than half of Albertans would consent to a supervised injection site “anywhere in their municipality” (46%, six points lower than the Canadian average), about three in 10 would welcome one “anywhere in their neighbourhood” (29%, nine points lower than the Canadian average) and fewer than one in four would approve of one “a block away from home” (22%, 10 points lower than the Canadian average).

We also sought to learn about the perceptions of Canadians on different varieties of addiction treatment.

Across the country, more than half of Canadians (57%) express support for “treatment that does not rely on opioid replacement therapy and aims for abstinence.” Approval for “treatment that does not aim for abstinence and relies on opioid replacement therapy” is significantly lower at 48%.

An addiction treatment program that aims for abstinence is particularly important for Albertans (65%), Atlantic Canadians (62%) and British Columbians (60%). •

Mario Canseco is president of Research Co.

Results are based on an online study conducted from July 15 to July 17, 2019, among 1,000 adults in Canada. The data has been statistically weighted according to Canadian census figures for age, gender and region in Canada. The margin of error, which measures sample variability, is plus or minus 3.1 percentage points, 19 times out of 20.